Miwa, Kunihisa · Internal medicine (Tokyo, Japan) · 2021 · DOI
Researchers tested whether minocycline, an antibiotic that may reduce brain inflammation, could help ME/CFS patients. About 27% of 100 patients taking minocycline for 6 weeks experienced meaningful symptom improvement, particularly those who had been sick for less than 3 years. However, 38% of patients had to stop taking it early due to side effects like nausea and dizziness.
This is among the first clinical explorations of minocycline's neuroprotective properties in ME/CFS patients, offering a potential therapeutic avenue targeting neuroinflammation. The finding that early-stage patients respond better suggests a time-sensitive window for intervention, which could inform treatment timing strategies. If validated in controlled trials, this could provide patients—especially those newly diagnosed—with an additional evidence-based treatment option.
This study does not prove minocycline is an effective ME/CFS treatment; it is observational without a placebo or control group, so symptom improvements could reflect natural variation, placebo response, or other factors. The high discontinuation rate (38%) and modest response rate (27%) mean the drug's actual clinical utility remains unclear. This finding does not establish that neural inflammation is the cause of ME/CFS, only that minocycline may benefit some patients, particularly early in disease.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.